Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BeiGene Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public

Established: 2010-01-01

Employees: 10K

Market Cap: $22.1B

Website: http://www.beigene.com

Clinical Trials

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Phase 1

Recruiting

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Waldenström Macroglobulinemia
Follicular Lymphoma
Non-Hodgkin Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
B-cell Malignancy
Richter's Transformation
DLBCL Unclassifiable

Interventions: Drug: BGB-16673

First Posted Date: 2022-03-24

Last Posted Date: 2025-04-20

Lead Sponsor: BeiGene

Target Recruit Count: 146

Registration Number: NCT05294731

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

and more 26 locations

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Phase 1

Completed

Conditions: Relapsed Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma

Interventions: Drug: Ociperlimab
Drug: Tislelizumab
Drug: Rituximab

First Posted Date: 2022-03-04

Last Posted Date: 2024-12-27

Lead Sponsor: BeiGene

Target Recruit Count: 53

Registration Number: NCT05267054

Locations: 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

and more 16 locations

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Tislelizumab

First Posted Date: 2021-11-10

Last Posted Date: 2025-03-13

Lead Sponsor: BeiGene

Target Recruit Count: 33

Registration Number: NCT05116085

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
The Affiliated Hospital of Qingdao University Branch South, Qingdao, Shandong, China
🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

and more 5 locations

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Phase 3

Recruiting

Conditions: Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Rituximab
Drug: Obinutuzumab
Drug: Lenalidomide

First Posted Date: 2021-10-29

Last Posted Date: 2025-06-24

Lead Sponsor: BeiGene

Target Recruit Count: 780

Registration Number: NCT05100862

Locations: 🇺🇸
Ucsf Fresno University of California San Francisco Fresno, Fresno, California, United States
🇺🇸
Kaiser Permanente Southern California, Irvine, California, United States
🇺🇸
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States

and more 286 locations

First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants

Phase 1

Completed

Conditions: Not Determined

Interventions: Drug: BGB-23339
Drug: Placebo

First Posted Date: 2021-10-26

Last Posted Date: 2024-10-23

Lead Sponsor: BeiGene

Target Recruit Count: 92

Registration Number: NCT05093270

Locations: 🇦🇺
Q PHARM, Herston, Queensland, Australia
🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
🇨🇳
The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao, Shandong, China

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Phase 2

Active, not recruiting

Conditions: Relapsed Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma

Interventions: Drug: Zanubrutinib

First Posted Date: 2021-10-05

Last Posted Date: 2025-04-16

Lead Sponsor: BeiGene

Target Recruit Count: 66

Registration Number: NCT05068440

Locations: 🇨🇳
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

and more 22 locations

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

Phase 2

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: lenvatinib
Drug: Tislelizumab

First Posted Date: 2021-08-20

Last Posted Date: 2024-11-28

Lead Sponsor: BeiGene

Target Recruit Count: 58

Registration Number: NCT05014828

Locations: 🇨🇳
The Second Hospital of Anhui Medical Hospital, Hefei, Anhui, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Beijing Luhe Hospital, Beijing, Beijing, China

and more 13 locations

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)
Nonsmall Cell Lung Cancer, Stage IV

Interventions: Drug: Ociperlimab
Drug: Tislelizumab
Drug: histology-based chemotherapy
Drug: Placebo

First Posted Date: 2021-08-20

Last Posted Date: 2024-12-06

Lead Sponsor: BeiGene

Target Recruit Count: 272

Registration Number: NCT05014815

Locations: 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Comprehensive Cancer Center of Nevada, Henderson, Nevada, United States

and more 73 locations

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Phase 1

Recruiting

Conditions: Marginal Zone Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma
B-cell Malignancy
Small Lymphocytic Lymphoma
Follicular Lymphoma
Waldenström Macroglobulinemia
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: BGB-16673

First Posted Date: 2021-08-16

Last Posted Date: 2025-06-24

Lead Sponsor: BeiGene

Target Recruit Count: 621

Registration Number: NCT05006716

Locations: 🇺🇸
University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸
Western Regional Medical Center, Llc, Goodyear, Arizona, United States
🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States

and more 114 locations

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Resectable Esophageal Squamous Cell Carcinoma

Interventions: Drug: Tislelizumab

First Posted Date: 2021-07-23

Last Posted Date: 2024-11-27

Lead Sponsor: BeiGene

Target Recruit Count: 70

Registration Number: NCT04974047

Locations: 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy